ArticleScientific reports2026
Exploring the toxicological effects of Di-O-benzoyldiethylene glycol plasticizer on allergic rhinitis through network toxicology combined with molecular docking and molecular simulation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Di-O-benzoyldiethylene glycol, a novel eco-friendly plasticizer, lacks sufficient toxicological data, particularly regarding allergic rhinitis (AR). This study aims to elucidate its molecular mechanisms in AR induction and provide theoretical insights for targeted therapeutic strategies. Through network toxicology, molecular docking, and dynamics simulations, we retrieved Di-O-benzoyldiethylene glycol structures from PubChem, predicted its targets with multifaceted database analyses, and identified AR-related targets. Bioinformatics analysis highlighted immune and inflammatory pathways as key links and identified five core targets: AKT1, BCL2, EGFR, ESR1, and TNF. Molecular docking technology confirmed their strong binding affinity with AKT1, BCL2, EGFR, and ESR1.Molecular docking simulations indicate a high affinity binding between Di-O-benzoyldiethylene glycol and TNF, suggesting an effective interaction.In summary, Di-O-benzoyldiethylene glycol may promote the development of AR by regulating immune and inflammatory responses.These studies will provide important theoretical basis for preventing the progression of allergic diseases and evaluating the health risks of environmental pollution caused by new plasticizers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.